Skip to main content
23, Oct 2022

Rapid six-hour test panel to predict CMV infection and transplant rejection

Plexision, a biotechnology company, is offering the first blood test panel capable of reporting the risk of cytomegalovirus infection and transplant rejection within six hours after samples arrive at its reference laboratory.


Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.